February, 2003
© 2000 Scott S. Emerson, M.D., Ph.D.
Session
4:
58
Case Study 1: Idarubicin in AML
Initial design
Fixed sample study
Two-sided level 0.05 hypothesis test
80% power to detect absolute difference in
response rates of 0.20
90 patients per treatment arm